• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

    9/30/24 5:40:03 PM ET
    $RFL
    Real Estate
    Finance
    Get the next $RFL alert in real time by email
    SC 13D/A 1 ea0216209-13da4jonas_rafael.htm AMENDMENT NO. 4 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 4)

     

    RAFAEL HOLDINGS, INC.

     

    (Name of Issuer)

     

    Class B Common Stock, par value $0.01 per share

     

    (Title of Class of Securities)

     

    75062E106

     

    (CUSIP Number)

     

    Howard S. Jonas

    520 Broad Street

    Newark, NJ 07102

    (973) 438-1000

     

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    September 25, 2024

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box: ☐

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13D/A

     

    This Amendment No. 4 to Schedule 13D (this “Amendment”) supplements and amends the information contained in the Schedule 13D originally filed with the Securities and Exchange Commission (the “Commission”) on April 12, 2018, as previously amended by Amendment No. 1, thereto filed with the Commission on February 27, 2023, Amendment No. 2, thereto filed with the Commission on August 3, 2023, and Amendment No. 3, thereto filed with the Commission on June 18, 2024 (as so amended, the “Schedule 13D”).

     

    Item 2. Identity and Background

     

    Item 2 of the Schedule 13D is hereby amended and supplemented as follows:

     

    On September 25, 2024, the Commission issued an order instituting administrative proceedings against Howard S. Jonas regarding issues related to the timeliness of certain filings on Schedule 13D and the required amendments related to his beneficial ownership in four different companies, including Rafael Holdings, Inc. (the “Order”). The Order also contains the terms of the settlement of those proceedings, which include a cease-and-desist order concerning violations of Sections 13(d) of the Exchange Act and Rules 13d-1 and 13d-2 promulgated thereunder and a civil penalty of $90,000. Mr. Jonas consented to the Order without admitting or denying any of the findings or charges (other than the SEC’s jurisdiction). The Order does not include any scienter-based charges or findings against Mr. Jonas. The Order also noted that information concerning Mr. Jonas’s beneficial ownership interests in the four companies was disclosed separately in other filings with the Commission.

     

    2

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: September 30, 2024

     

    /s/ Joyce J. Mason  
    Joyce J. Mason  
    Attorney-in-Fact  

     

    3

     

    Get the next $RFL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RFL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RFL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec Chairman, CEO & President Jonas Howard S bought $16,742,985 worth of Class B Common Stock (13,080,457 units at $1.28) (SEC Form 4)

    4 - Rafael Holdings, Inc. (0001713863) (Issuer)

    6/9/25 5:19:19 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

    Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their review of prespecified safety and efficacy date at 48 weeks On August 4, 2025, Joshua Fine was elected as the Company's Chief Operating Officer NEWARK, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL), today reported its financial results for the fourth quarter and full fiscal year 2025 ended July 31, 2025. "We are pleased with the continued progress of our pivotal Phase 3 TransportNPC™ study evaluatin

    10/29/25 4:24:40 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

    NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. Mr. Grayson will serve on the Compensation, Corporate Governance and Nominating Committees. Separately, the Company also announced that Markus Sieger, an existing Board member, will join the Audit Committee as its Chair and has been elected as Lead Independent Director. Stephen Greenberg had served on Rafael's Board since March 2018 bringing with him a wealth of experience, insights, and guidance. Mr. Greenberg had served as a director of Zedge, Inc. f

    10/28/25 4:01:00 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

    First data on treatment of NPC1 with Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients1 showed stabilization or improvement in CGI-S score Data presented at the15th International Congress of Inborn Errors of Metabolism (ICIEM) NEWARK, N.J., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) announced today that data from Cyclo Therapeutics' Phase 3 TransportNPC™ open-label, single-arm sub-study evaluating Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick Disease Type C1 ("NPC1") were presented at the 15th International Congress of Inborn Errors of Metab

    9/16/25 8:00:00 AM ET
    $RFL
    Real Estate
    Finance

    $RFL
    SEC Filings

    View All

    SEC Form 10-K filed by Rafael Holdings Inc.

    10-K - Rafael Holdings, Inc. (0001713863) (Filer)

    10/29/25 5:19:30 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Rafael Holdings, Inc. (0001713863) (Filer)

    10/29/25 4:36:55 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Rafael Holdings, Inc. (0001713863) (Filer)

    10/28/25 4:11:34 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Grayson Alan claimed no ownership of stock in the company (SEC Form 3)

    3 - Rafael Holdings, Inc. (0001713863) (Issuer)

    10/31/25 3:07:03 PM ET
    $RFL
    Real Estate
    Finance

    Chief Financial Officer Polinsky David covered exercise/tax liability with 4,180 units of Class B Common Stock, decreasing direct ownership by 2% to 260,641 units (SEC Form 4)

    4 - Rafael Holdings, Inc. (0001713863) (Issuer)

    10/28/25 3:12:55 PM ET
    $RFL
    Real Estate
    Finance

    Chief Financial Officer Polinsky David covered exercise/tax liability with 1,284 units of Class B Common Stock, decreasing direct ownership by 0.48% to 264,821 units (SEC Form 4)

    4 - Rafael Holdings, Inc. (0001713863) (Issuer)

    9/25/25 2:34:43 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Leadership Updates

    Live Leadership Updates

    View All

    Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

    NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. Mr. Grayson will serve on the Compensation, Corporate Governance and Nominating Committees. Separately, the Company also announced that Markus Sieger, an existing Board member, will join the Audit Committee as its Chair and has been elected as Lead Independent Director. Stephen Greenberg had served on Rafael's Board since March 2018 bringing with him a wealth of experience, insights, and guidance. Mr. Greenberg had served as a director of Zedge, Inc. f

    10/28/25 4:01:00 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

    Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

    8/22/24 6:50:00 AM ET
    $CYTH
    $RFL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Finance

    Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

    Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

    8/22/24 6:50:00 AM ET
    $CYTH
    $RFL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Finance

    $RFL
    Financials

    Live finance-specific insights

    View All

    Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

    Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy Rafael Holdings to Host Conference Call Today at 8:00 a.m. ET NEWARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE:RFL), a holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute, investment in Rafael Pharmaceuticals, Inc. ("Rafael Pharmaceuticals") as well as other investments in early-stage ventures, today announced that the AVENGER 500 Phas

    10/28/21 7:00:00 AM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

    SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

    9/30/24 5:40:03 PM ET
    $RFL
    Real Estate
    Finance

    Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

    SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

    6/18/24 6:12:11 PM ET
    $RFL
    Real Estate
    Finance

    SEC Form SC 13D/A filed by Rafael Holdings Inc. (Amendment)

    SC 13D/A - Rafael Holdings, Inc. (0001713863) (Filed by)

    10/24/23 4:43:18 PM ET
    $RFL
    Real Estate
    Finance